Houston Gilbert

1.8k total citations
25 papers, 782 citations indexed

About

Houston Gilbert is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Houston Gilbert has authored 25 papers receiving a total of 782 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in Houston Gilbert's work include Cancer Immunotherapy and Biomarkers (7 papers), Prostate Cancer Treatment and Research (6 papers) and Adenosine and Purinergic Signaling (4 papers). Houston Gilbert is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Prostate Cancer Treatment and Research (6 papers) and Adenosine and Purinergic Signaling (4 papers). Houston Gilbert collaborates with scholars based in United States, Switzerland and Germany. Houston Gilbert's co-authors include Peter M. Haverty, Mark J. van der Laan, Sandrine Dudoit, David A. Fox, Judith Endres, Jason A. Hackney, Sarah Kummerfeld, Cécile Holweg, Wei Lin and David Musselman and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Houston Gilbert

24 papers receiving 770 citations

Peers

Countries citing papers authored by Houston Gilbert

Since Specialization

Citations

This map shows the geographic impact of Houston Gilbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Houston Gilbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Houston Gilbert more than expected).

Fields of papers citing papers by Houston Gilbert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Houston Gilbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Houston Gilbert. The network helps show where Houston Gilbert may publish in the future.

Co-authorship network of co-authors of Houston Gilbert

This figure shows the co-authorship network connecting the top 25 collaborators of Houston Gilbert. A scholar is included among the top collaborators of Houston Gilbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Houston Gilbert. Houston Gilbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy 2024 ·Kidney International Reports ·Brad H. Rovin, Pierre Ronco, Jack F.M. Wetzels, Sharon G. Adler, Isabelle Ayoub, Philippe Zaoui, Seung Hyeok Han, Jaideep S. Dudani, Houston Gilbert, Uptal D. Patel, Paul T. Manser, (unknown), (unknown), Rainer Boxhammer, (unknown), Ben Sprangers	12
2	Felzartamab Reduces aPLA2R Ab by Selectively Depleting CD38+ Plasma Cells and Plasmablasts, the Main Pathogenic Cellular Drivers of Disease in Primary Membranous Nephropathy (PMN) 2023 ·Journal of the American Society of Nephrology ·(unknown), Rainer Boxhammer, (unknown), (unknown), (unknown), (unknown), Houston Gilbert, Uptal D. Patel, Brad H. Rovin	1
3	ARC-4 study: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC). 2020 ·Journal of Clinical Oncology ·Alexander I. Spira, Paul Conkling, Melissa L. Johnson, Olivia Gardner, Houston Gilbert, (unknown), F Yin, Kartik Krishnan, Melissa Paoloni, Arvind Chaudhry	9
4	A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer. 2020 ·Journal of Clinical Oncology ·David R. Wise, Olivia Gardner, Houston Gilbert, (unknown), Melissa Paoloni, Kartik Krishnan	4
5	Abstract LB-387: Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3) 2020 ·Cancer Research ·Michael Cecchini, Manuel Modiano, Fadi Braiteh, Olivia Gardner, Houston Gilbert, Daniel DiRenzo, Lisa Seitz, (unknown), F Yin, (unknown), Melissa Paoloni, Ki Y. Chung	1
6	Can Graphics Tell Lies? A Tutorial on How To Visualize Your Data 2018 ·Clinical and Translational Science ·Christopher R. Cabanski, Houston Gilbert, Sofia Mosesova	2
7	CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis 2018 ·PLoS ONE ·James Ziai, Houston Gilbert, Oded Foreman, Jeffrey Eastham‐Anderson, Felix Chu, Mahrukh Huseni, Jeongmin Kim	36
8	Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch 2017 ·Clinical and Translational Science ·Heleen Scheerens, (unknown), (unknown), Zachary Boyd, Vivek P. Gupta, Jeffrey M. Harris, (unknown), (unknown), Hieronymus P. Stevens, Houston Gilbert, (unknown), Rasika Kalamegham, (unknown), Jutta Engel, (unknown), Laurent Essioux, John A. Williams	81
9	A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study) 2016 ·Cancer ·Vicky Makker, Fernando O. Recio, Ling Ma, Ursula A. Matulonis, Jennifer Lauchle, Hema Parmar, Houston Gilbert, Joseph A. Ware, Rui Zhu, Shan Lu, Ling‐Yuh Huw, Yulei Wang, Hartmut Koeppen, Jill M. Spoerke, Mark R. Lackner, Carol Aghajanian	64
10	A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. 2016 ·Journal of Clinical Oncology ·Jeffrey R. Infante, Aaron R. Hansen, Michael J. Pishvaian, Laura Q.M. Chow, Grant A. McArthur, Todd M. Bauer, Stephen V. Liu, Shahneen Sandhu, Frank Tsai, Jeong Kim, Eric Stefanich, Chi‐Chung Li, Houston Gilbert, Bruce McCall, Maria Anderson, Mahrukh Huseni, Ina Rhee, Lillian L. Siu, Michael S. Gordon	55
11	Abstract 4310: Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) 2015 ·Cancer Research ·Daniel C. Danila, Howard I. Scher, Edith Szafer‐Glusman, (unknown), (unknown), Martin Fleisher, Nicole A. Schreiber, Kristen Curtis, Houston Gilbert, Daniel Maslyar, Bernard M. Fine, Ron Firestein, Michael Mamounas, Mark R. Lackner, Omar Kabbarah	1
12	STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC). 2015 ·Journal of Clinical Oncology ·Daniel C. Danila, Martin Fleisher, Jorge A. Carrasquillo, Houston Gilbert, Michael J. Morris, (unknown), (unknown), Edith Szafer‐Glusman, (unknown), Chintan Patel, Nicole A. Schreiber, Kristen Curtis, Daniel Maslyar, Vanessa Lemahieu, Bernard M. Fine, Michael Mamounas, Alexander Ungewickell, Mark R. Lackner, Howard I. Scher, Omar Kabbarah	4
13	Heterogeneity of cytotoxic T cell infiltration in breast and colorectal cancer 2015 ·Journal for ImmunoTherapy of Cancer ·James Ziai, Houston Gilbert, Oded Foreman, Jeffrey Eastham‐Anderson, Felix Chu, Mahrukh Huseni, Jeong Kim	0
14	Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics 2014 ·Arthritis Research & Therapy ·Glynn Dennis, Cécile Holweg, Sarah Kummerfeld, David F. Choy, Audi Setiadi, Jason A. Hackney, Peter M. Haverty, Houston Gilbert, Wei Lin, Lauri Diehl, Sven Fischer, (unknown), David Musselman, Micki Klearman, Cem Gabay, Arthur Kavanaugh, Judith Endres, David A. Fox, Flavius Martin, Michael J. Townsend	265
15	Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results. 2014 ·Journal of Clinical Oncology ·Vicky Makker, Fernando O. Recio, Ling Ma, Ursula A. Matulonis, Jennifer Lauchle, Hema Parmar, Houston Gilbert, Yulei Wang, Hartmut Koeppen, Jill M. Spoerke, Mark R. Lackner, Carol Aghajanian, (unknown)	12
16	A phase I study of DSTP3086S, an antibody-drug conjugate (ADC) targeting STEAP-1, in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). 2014 ·Journal of Clinical Oncology ·Daniel C. Danila, Russell Z. Szmulewitz, Ari David Baron, Celestia S. Higano, Howard I. Scher, Michael J. Morris, Houston Gilbert, Flávia Brunstein, Vanessa Lemahieu, Omar Kabbarah, Bernard M. Fine, Daniel Maslyar, Ulka N. Vaishampayan	15
17	Utilizing Design of Experiments to Characterize Assay Robustness 2012 ·Bioanalysis ·Kyra J. Cowan, Rich Erickson, (unknown), (unknown), Bert Gunter, (unknown), Houston Gilbert, An Song, Saloumeh K Fischer	4
18	Joint Multiple Testing Procedures for Graphical Model Selection with Applications to Biological Networks 2009 ·Collection of Biostatistics Research Archive ·Houston Gilbert, Mark J. van der Laan, Sandrine Dudoit	3
19	Resampling-Based Multiple Hypothesis Testing with Applications to Genomics: New Developments in the R/Bioconductor Package multtest 2009 ·Collection of Biostatistics Research Archive ·Houston Gilbert, Katherine S. Pollard, Mark J. van der Laan, Sandrine Dudoit	35
20	Resampling‐Based Empirical Bayes Multiple Testing Procedures for Controlling Generalized Tail Probability and Expected Value Error Rates: Focus on the False Discovery Rate and Simulation Study 2008 ·Biometrical Journal ·Sandrine Dudoit, Houston Gilbert, Mark J. van der Laan	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact